BlinkLab

BlinkLab ROE

The Return on Equity (ROE) of BlinkLab (BB1.AX) as of Oct 27, 2026 is -37.03 %. In the previous year, Return on Equity (ROE) was -63.62 % — a change of -41.80% (higher).

ROE

-37.03 %

YoY

-41.80%

Last updated:

In 2026, BlinkLab's return on equity (ROE) was -37.03 %, a -41.80% increase from the -63.62 % ROE in the previous year.

The BlinkLab ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2022
-67.65 AUD
Jan 1, 2023
-1,661.05 AUD
Jan 1, 2024
-27.04 AUD
Jan 1, 2025
-63.62 AUD
Jan 1, 2026
-37.03 AUD
The BlinkLab ROE history
YEARROEYoY
-37.03 %-41.80%
-63.62 %+135.28%
-27.04 %-98.37%
-1,661.05 %+2,355.20%
-67.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BlinkLab Stock analysis

What does BlinkLab do? BlinkLab Ltd offers the BlinkLab Dx system, comprising the BlinkLab App and BlinkLab Portal, to conduct neurobehavioral tests for diagnosing neurological disorders. The BlinkLab App enables patients, caregivers, and parents to complete tests in real time, while the BlinkLab Portal provides secure database management, CMS, and tools for customizing neurometric tests, data analysis, and visualization. The company generates revenue through the sale of these products to healthcare providers, research institutions, and clinics seeking cost-effective diagnostic solutions for neurological and psychiatric conditions. The BlinkLab Tests, including eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI), and habituation of eye blink response, serve as biomarkers for such disorders, making the system valuable for early detection and monitoring. Healthcare providers, research institutions, and clinics purchase the BlinkLab Dx system to integrate objective neurobehavioral testing into their diagnostic workflows. The BlinkLab App collects real-time data from test subjects, and the BlinkLab Portal allows for comprehensive data management and analysis, supporting both clinical and research applications. The company’s focus on biomarkers like EBC, PPI, and habituation of eye blink response positions it as a key tool for diagnosing disorders such as schizophrenia, ADHD, and autism spectrum disorders, which are increasingly recognized in clinical practice. The BlinkLab Tests, including eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI), and habituation of eye blink response, are marketed as objective biomarkers for neurological and psychiatric disorders. By leveraging mobile technology, BlinkLab Ltd provides a cost-effective alternative to traditional diagnostic methods, appealing to institutions looking to streamline their diagnostic processes. The company’s revenue model relies on selling the BlinkLab App and Portal as integrated solutions, with no mention of additional services or third-party partnerships in the business description. BlinkLab is one of the most popular companies on Eulerpool.

ROE Details

Decoding BlinkLab's Return on Equity (ROE)

BlinkLab's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing BlinkLab's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

BlinkLab's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in BlinkLab’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about BlinkLab stock

Return on Equity (ROE) of BlinkLab is -37.03 % in 2026.

Return on Equity (ROE) of BlinkLab changed from -63.62 % to -37.03 %, representing a -41.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) BlinkLab since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s BlinkLab with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — BlinkLab

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — BlinkLab